Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer’s Disease
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals that provides Acumen access to Halozyme’s ENHANZE® drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous drug delivery, for a…
Talking About Neuropsychiatric Symptoms of Alzheimer’s Disease
The Alliance for Aging Research introduces a novel video series aimed at educating the public on neuropsychiatric symptoms (NPS) associated with Alzheimer’s disease. These videos aim to de-stigmatize NPS, fostering discussions about care plans and supporting Alzheimer’s patients who deserve…
